---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157096"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2025-07-09T23:59:59+00:00"
generated_at: "2026-05-18T08:52:21.772832+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029

## Summary
- Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.
- Agreement term extended to November 25, 2029.
- Exclusivity period extended to December 31, 2028 for both parties on tumor-informed MRD in these indications.
- Standstill restrictions for Tempus modified to expire June 4, 2027 or end of exclusivity.

## SEC filing metadata
- accession: 0001193125-25-157096
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2025-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312525157096/0001193125-25-157096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312525157096/d26859d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157096
- JSON: https://secwatch.observer/filing/0001193125-25-157096.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.